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ABSTRACT 
Bacterial co-infections with influenza A virus (IAV) are extremely serious and life-threatening. 
However, there exists limited understanding about the importance of fungal infections with IAV. 
Clinical case reports indicate that fungal co-infections do occur and suggest the IAV pandemic of 
2009 had a propensity to predispose patients to secondary fungal infections more than previous 
IAV strains. IAV-fungal co-infections are marked by high mortality rates of 47 to 61% in 
previously healthy individuals between the ages of 20 and 60. Yet, the variables involved in this 
co-infection remain undetermined. I achieved effective recapitulation of this co-infection using a 
C57Bl/6 murine (mouse) model which resulted in similar morbidity and mortality rates seen in 
humans. Here, I proposed that an exacerbated immune response during infection with IAV and 
the opportunistic saprophytic ubiquitous fungal pathogen, Aspergillus fumigatus, induces the 
development of more severe pneumonia. I explored the possible mechanisms regulating 
inflammation at the cellular level. To do this, a cellular model was designed using primary 
mouse bone marrow derived macrophages (BMDMs) infected first with IAV and later co-
infected with A. fumigatus. Our in vitro data indicated that IAV and fungal co-infections 
synergistically enhanced immune cell signaling and pro-inflammatory cytokine production 
through the caspase-1 containing inflammasome. Through various immunological techniques, I 
established that, during co-infection, AIM2 mediated maturation of caspase-1 facilitates the 
observed increase in production of pro-inflammatory cytokines. Interestingly, enhanced caspase-
1 maturation is not due to increased NLRP3 inflammasome priming. NLRP3 expression actually 
diminishes over the course of infection, which could be explained through increased proteasomal 
degradation of NLRP3 through dysregulated DAPK1 signaling. 
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INTRODUCTION 
 
Over the last century, the field of immunology, through great strides, has made 
meaningful contributions to science through prolonging and improving the quality of life. As our 
repertoire of knowledge about the immune system continues to evolve, interestingly, so does the 
causative agents of infectious diseases we must combat daily. Immunologists, as detectives, have 
plenty of clues left to investigate. As new pathogens emerge, old pathogens mutate and/or evolve 
and continue to infect the human population. Host-pathogen interactions are a large portion of 
understanding how populations succumb to disease. Some interactions are multivariate. Some 
diseases occur with multiple pathogens infecting the same host, a phenomenon known as co-
infections. A co-infection is simply two pathogens successfully infecting the host in sequential 
order, and the order of infection is often essential. These interactions are the premise of the 
research to be elaborated further in this thesis. 
Much like a thrilling mystery novel, there exists a constant struggle between the 
protagonist (the host) and the antagonist (the pathogen). The pathogen is consistently developing 
mischievous methods to invade or evade the host. Our story begins with a recent example in 
human history of a host-pathogen battle, the influenza A pandemic of 2009. Medical 
professionals and immunologists were puzzled by this pandemic, in particular, by an explicit 
population of young, previously healthy individuals who became ill and died –a population not 
noticeably plagued by pandemic strains in recorded history [1]. The primary pathogen was 
influenza A virus (IAV). IAV has claimed many lives throughout the last century [2]. IAV, after 
infecting the host, initiates a robust immune response, which results in taxing of the body’s 
resources. Interestingly, IAV usually does not possess the virulence to kill someone on its own, 
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but the depletion of the hosts ability to clear this primary pathogen allows a secondary or 
opportunistic pathogen, such as a fungus, Aspergillus fumigatus for example, to occupy the host 
[3]. Together, these two pathogens are the culprits of a devastating disease with mortality rates 
ranging from 47 to 61% in these co-infected (but initially immunocompetent) individuals [4].  
While IAV-bacterial co-infections are well defined, our understanding of co-infections 
with fungus as the major co-infecting agent is severely lacking. Interestingly, this co-infection 
still leaves medical professionals baffled by the lack of treatments to successfully prevent such 
high mortality rates over the last decade. Therefore, growing awareness of these co-infections 
arises from their occurrence, especially in recent years [5].  
For scientists, the goal is to make a contribution to ‘solve’ this mystery or understand 
how these two antagonists successfully destroy the protagonist together in this increasingly 
prevalent viral-fungal co-infection. The development of the disease is likely associated with the 
specific immune responses to IAV and A. fumigatus. It must be noted that the response of the 
immune system to each of these pathogens is quite different. To generally understand this co-
infection, one must first obtain a foundational understanding of these causative agents involved 
and their unique immune responses separately. Improved understanding of the pathogens 
themselves, and the immune responses they elicit, will facilitate new research into improving the 
effectiveness of available treatments.  
 
Influenza A virus 
Influenza A virus (IAV), a common, but significant human respiratory pathogen, has 
affected us all in one way or another. Ranging from mild illness to life threatening infections, 
most of us have suffered from the seasonal flu.  
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History. IAV remains responsible for the killing of millions of people. The most 
notorious IAV pandemic was the devastating 1918-1919 H1N1 ‘Spanish Flu’ pandemic, and 
IAV still remains a global threat to human health yearly via seasonal pandemics [6].  Despite 
development of an ever-changing vaccine in response to mutating IAV existing for the last 70 
years, seasonal and pandemic influenza infections remain prevalent. Other influenza pandemics 
have occurred but were less severe. Specifically, the most recent flu pandemic, the 2009 H1N1 
‘Swine Flu’, surfaced in the United States (USA) and Mexico [7]. The Swine Flu emerged in 
April and by June, the World Health Organization (WHO) classified this specific strain as a 
pandemic virus [8].  
Characteristics. Belonging to the Orthomyxoviridae family, IAV is one of three genera 
of influenza viruses infectious to humans, influenza A, B and C [9]. IAV is an enveloped virus.  
The envelope is a lipid membrane surrounding the virion derived from the host cell plasma 
membrane [10]. The IAV genome consists of eight separate segments of negative-sense single-
stranded RNA (entire genetic material). Two important glycoprotein antigens project from the 
virion’s surface: haemagglutinin, HA (of which there are 18 versions, H1 – H18) and 
neuraminidase, NA (with versions N1 –N11) [11]. The 18 variants of HA and 11 variants of NA 
glycoproteins contribute to further subdividing IAV [12]. IAV strains are referred to by the 
associated nomenclature through the HA and NA specific to the virus – H1N1 [13-15]. IAV has 
additional proteins including the nucleoprotein (NP), responsible for aiding in viral replication, 
and an internal coat of matrix proteins (M1 and M2), which function as mediators for exporting 
of viral ribonucleoproteins from the host cell nucleus and virus assembly and exit [16-18]. The 
remaining segments of the RNA genome of IAV encode for molecular machinery proteins 
known generally as polymerases. These polymerase complex proteins, polymerase basic proteins 
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(PB1/2) and polymerase acidic protein (PA) together are the subunits that form a trimeric viral 
RNA-dependent RNA polymerase [19-22]. Genome replication and mRNA transcription from 
the RNA viral genome by these RNA polymerases occurs within the nucleus of infected host 
cells [23]. Lastly, NS1 (nonstructural protein) and PB1-F2 (part of the viral RNA polymerase) 
are important in viral virulence through blocking antiviral immune responses (interferons) within 
the host cell [24-27]. 
Gene Re-assortment. The 2009 strain of IAV was unique. The genes involved were not 
previously identified together in any of the common reservoirs of influenza before –human, 
avian and other mammals, like swine. Therefore, this pandemic (H1N1) 2009 virus consisted of 
multiple re-assorted genes from diverse organism origins [28]. This pandemic (H1N1) 2009 
virus is currently the only IAV strain with an animal reservoir that can sufficiently transmit 
infection to humans. The ability to transmit from an animal reservoir to humans has been 
associated with pandemic viruses reported throughout history and is one major reason why it is 
studied [29]. Recall the segmented genome of IAV mentioned previously. This segmented 
genome structure facilitates the exchange of genes between different strains of influenza that 
have infected the same host cell (antigenic shift). Such genetic re-assortment poses a significant 
risk of zoonotic infection through host switching [30]. Importantly, this pandemic (H1N1) 2009 
virus underwent genetic translocation from three different IAV strains and expedited the 
generation of a novel pandemic strain of IAV in 2009 [31]. The genome of IAV H1N1 2009 was 
composed of one genetic segment from human IAV H3N2, two segments of avian IAV H1N1 
and the remaining five segments originating from swine IAV H1N1 [32]. Thus, the addition of 
swine as a confirmed mixing vessel for influenza viruses contributes to increased host range and 
virulence of IAV in mammals [33-35].  
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Transmission. The 2009 H1N1 strain of IAV was also different from most seasonal 
IAVs, because it affected mainly teens, young adults and adults instead of the common 
propensity of most IAVs to affect the very young or elderly [36]. This pattern of infectivity was 
likely due to previous IAV (H1N1) strains circulating amongst the human population for decades 
prior to this specific exposure with the 2009 pandemic strain [37]. Transmission of IAV occurs 
normally through inhalation of virus-laden air-droplets, contact with contaminated objects, also 
called fomites, and by direct contact with infected individuals [38]. Post inhalation of aerosols, 
IAV, an obligate intracellular parasite, targets the pseudostratified columnar epithelial cells of 
the trachea and bronchial tree [39].  
Viral Factors Implicating Infection Severity. Previous exhaustive research of IAV co-
infections with bacterial pathogens, especially with Streptococcus pneumoniae, have highlighted 
the severity of a primary viral infection to be associated with the specifics of HA and NA surface 
antigen types randomly resulting from viral re-assortment [40-42]. Due to the specificity of HA 
binding to α2,6-sialylated glycans (cellular glycoprotein receptors) present on the cellular 
membrane of unique respiratory epithelia previously mentioned and the host protease activity 
does impact the site and development of the strain of IAV infection depending on the strain [43-
44]. HA experiences a conformational change once the low pH within an endosome permits the 
successful penetration of the virion into the host cell. Highly pathogenic strains of IAV are 
cleaved inside host cells. NA must be complementary to and share the same receptor affinity of 
HA [45-46]. This NA affinity promotes ease of release of newly formed virion progeny through 
hydrolyzing the sialic acid to facilitate virion detachment from the host cell [47-48]. IAV can 
also produce a viral cytotoxin, PB1-F2. This cytotoxin actually has been linked to increasing 
inflammation and therefore host cell damage and actually the adherence of co/secondary 
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bacterial infecting agents, such as the mentioned S. pneumoniae [49-52]. Alarmingly, the 
predicted superinfections reported were of different types during the 2009-2010 flu season in 
comparison to the 1918 H1N1 pandemic due to the use of antibiotics, supportive measures 
(ventilators) and vaccinations for S. pneumoniae. Therefore, the predicted reduction in S. 
pneumoniae co-infection were correct, a decrease to 30% [53], but there was a shift to co-
infection with S. aureus and A. fumigatus. The direct link of HA, NA and PB1-F2 and their 
involvement of co/secondary fungal infections with IAV have yet to be studied in detail. 
Pathogenesis. An infection with IAV causes a broad range of signs and symptoms in 
infected individuals. Commonly, the signs or symptoms of a positive IAV infection includes 
runny nose, congestion, muscle and headaches, dizziness, fatigue or malaise and fever [54]. The 
pathogenesis of IAV can be quite mild to severe. Interestingly, 2009 H1N1 is reported to be 
characterized also by the observed increased replication and pathological changes in the lungs of 
nonhuman primates and ex vivo human lung tissues [55]. Such observations could contribute to 
explaining the ability of this strain of IAV to cause severe viral pneumonitis in humans [56]. 
2009 H1N1 was predicted as a high-virulence virus like 1918 H1N1 and H5N1. High-virulence 
viruses such as these tend to infect pneumocytes and intra-alveolar macrophages [57-59]. Among 
the extensive list of co-infecting bacterial and other viral pathogens after IAV infection occurs, 
the 2009 pandemic strain of IAV is believed to have the propensity to predispose patients to 
opportunistic pathogens such as fungi like Aspergillus fumigatus [60].  
 
Aspergillus fumigatus (A. fumigatus) 
A. fumigatus is a ubiquitous, airborne saprophytic fungus. Its airborne spores are highly 
prevalent, and it is essential in the recycling of environmental carbon and nitrogen within the 
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earth’s soil by the decomposition organic debris [61].  Due to the ability of the innate immune 
systems of healthy individuals to eliminate the inhaled conidia spores and prevent infection with 
A. fumigatus, this fungus was considered an opportunistic weak pathogen until recently [62]. A. 
fumigatus is now considered to be there causal agent of the most common mold infection 
worldwide [63-64]!  
General Biology. A. fumigatus is ubiquitous, not only because of its prevalent and easily 
dispersed spores, but also due to several factors such a cell wall structure and the physiology of 
the vegetative biofilm generated through metabolism and responses to stress. The fungus can 
grow and survive at a wide range of temperatures (~12C to 37C+) and pH (3.7 to 6.7) [65]. 
The conidia spores are easily airborne upon starvation of the fungus. These asexual spores detach 
from specialized hyphal head structures, or conidiophores, to eventually become airborne and 
spread through wind currents after disturbance [66]. Conidiophores produce the conidia and aid 
in the spore’s transmission asexually. It was believed, until 2009, that A. fumigatus was 
reproducing exclusively asexually. But, conditions for sexual replication are explicit and non-
physiological due to the ascosphores (sexual cycle structure) remaining dormant until they 
successfully germinate above 65C [67]. The hyphae of A. fumigatus are responsible for the 
formation of fungal colony growth, or mycelium formation, after germination begins under 
optimal temperature, pH and humidity [68]. The colony eventually forms a biofilm, the 
vegetative form of this filamentous fungi that is made of an extracellular matrix of hyphae 
composed of embedded septated multinucleated cells [69]. It must be noted here that forms of 
the cell wall of the fungus differ between the multiple stages (conidial, mycelial/hyphal, biofilm) 
of A. fumigatus [70-71].  
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The cell wall composition of A. fumigatus continuously adapts over the life cycle of the 
fungus as the cell cycles progress and the environment of the fungus is altered [72]. 
Understanding why and how these fungal cell wall configurations exist remains a major 
challenge.  However, the organizational structure of the inner cell wall is thoroughly 
characterized. Generally, the inner portion of the cell wall is composed of cross-linked branches 
of -1,3-glucan/-1,4-glucan, galactomannan, galactosaminogalactan (GAG) and chitin –
constituting the insoluble, alkali skeleton [73-74]. Beginning with the conidial stage, the dense 
layer around the conidia contains -1,3-glucan, melanin and RodA hydrophobin [75]. The 
hyphal cell wall, succeeding germination, changes and the melanin and rodlet layer are shed to 
allow hyphal growth to proceed [76]. It must be noted that depending upon the environmental 
conditions A. fumigatus is experiencing, the hyphae may continue to contain melanin despite the 
shedding of that specific layer [77]. Previous research has highlighted that the gene required for 
the biosynthesis of melanin, PKSP, was upregulated within the lung environment of 
immunocompromised mice [78-79]. Therefore, melanin still remains a significant area of study 
for understanding the virulence of A. fumigatus and the resulting fungal diseases which lead to 
aspergillosis. It is known that the extracellular matrix composed of GAG, galactomannan, -1,3-
glucans and melanin facilitate the promotion of A. fumigatus infections [80]. 
For the metabolism of A. fumigatus to be effective, this fungus has adapted to a variety of 
nutritional requirements found in biological materials, also contributing to its ubiquity. The 
ability of the fungus to adapt to the vast variety of nutritional sources is associated with its wide 
range of protease and enzyme production. These proteases and enzymes allow not easily 
accessible nutrients to become obtainable. These proteases and enzymes facilitate the acquisition 
of essential cations from the host tissue such as iron and zinc [81]. Previous research highlighted 
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that the acquisition of nitrogen and carbon is crucial for initiating the early stages of infection 
[82]. Mutating the transcription factors that regulate these protease and enzyme genes (cross-
pathway control protein A (CpcA), AreA and CreA) resulted in reduced virulence observed in 
murine in vivo experiments [83]. A. fumigatus is actually an obligate aerobe, meaning that the 
fungus must have oxygen to survive [84-85]. However, A. fumigatus has developed a mechanism 
of strain/stress fitness under low oxygen conditions – contributing to virulence of the fungus. It 
was reported that A. fumigatus actually induces a gene that correlates to the production of sterol, 
SRBA (sterol regulatory element-binding protein gene). This gene initiates the biosynthesis of 
ergosterol. Low sterol levels are confirmed in fungi like A. fumigatus when in a hypoxic 
environment. Hypoxia actually facilitates proteolytic cleavage through Sre1 due to a loss of acyl-
CoA. The regulatory links between hypoxia adaptation, iron homeostasis and ergosterol 
biosynthesis remains with the fungal electron transport chain within the mitochondria and 
alcohol dehydrogenase [86-87, 289-290]. This, therefore, allows A. fumigatus to thrive in many, 
including the lungs of humans. 
Transmission. A. fumigatus fungus profusely conidiates because of the thousands of 
conidia produced by the conidial head. Dissemination of the conidia is not complicated; it is 
simply done through disturbances usually caused by strong air currents in the environment. Due 
to their small size and buoyancy, the conidia, once in the air, remain there. Therefore, it would 
make sense that at least hundreds to thousands of asexual spores are inhaled per person per day 
[88]. Airborne conidia, with their microscopic sizes of 2 –3 microns, can be inhaled deep into the 
lungs where they reach and settle into the alveoli [89]. The lung tissues, although not a normal 
niche for A. fumigatus, provides an environment rich in organic compounds and essential metals 
for the fungus to feed upon. A. fumigatus is normally no danger to healthy ‘immunocompetent’ 
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individuals due to the armory of defenses the innate immune system provides us. In 
immunocompetent individuals, resident alveolar macrophages, muco-ciliary action of the lung 
epithelial cells and nutritional immunity are just a few key mechanisms in host defense [90-92]. 
However, proteases and destructive enzymes permit the broad biological specificity of this 
fungus to achieve nourishment from within the human host. The explicit known proteases that A. 
fumigatus uses to enable growth include serine metalloproteinases, and aspartic proteases [93-
95]. Not surprisingly, much more research is needed to understand which pivotal proteases and 
enzymes destroy the human host for A. fumigatus’ survival.  
Aspergillus fumigatus remains one of the most challenging and poorly understood 
pathogens that can infect humans. The complexity of this nomad pathogen accelerates the urgent 
need to grasp its interaction with the host immune response.  
 
Relevant Immune System 
Maintaining homeostasis of the host is the vital role of the immune system, through the 
orchestration of cells, tissues and organs working together to protect and defend against the 
invasion of foreign agents. Intriguingly, all living things have an immune system of some kind. 
Humans, in particular, have complex immune systems, configured normally with sections of the 
innate and adaptive immune systems.  
Overview of Innate Immunity. During the first critical hours and days after exposure to 
an invader, the innate immune system acting as the ‘first line of defense’, is responsible for 
initiating a biological response to harmful stimuli –known as inflammation.  
Inflammation. The primary purpose of inflammation is the communication and migration 
of immune cells to the exact site where the trauma occurred. Without this response, the 
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infections, wounds and damage to tissue that the body experiences would not be able to heal 
efficiently. There exist five symptoms that are commonly known for acute inflammation, these 
include: redness, heat, swelling, pain and loss of function. So, what causes these five symptoms? 
The immune cells responding to a specific trauma release various chemical messages, known 
generally as inflammatory mediators [96-98]. These mediators include hormones: bradykinin and 
histamine. These two hormones cause a physiological reaction around the site of trauma known 
as vasodilation, therefore increasing blood flow to reach the injured tissue. Two of the five 
symptoms, redness and heat, are explained through this increase in blood flow due to the release 
of these mediators. The increased blood flow and vascular permeability in the injured area 
facilitates immune cell entry into the affected tissue. This process, scientifically known as 
diapedesis, is the movement of immune cells into tissue by passing through leaky blood vessel 
walls. Blood vessel leakiness and diapedesis are responsible for the swelling and pain 
experienced. Due to the pain, loss of function of the injured area results, causing the host to 
protect the affected portion of the body [99-106].  
Innate Immune Cells. Commonly known as white blood cells or leukocytes, immune cells 
come in all shapes, sizes and functions. These differentiated leukocytes originate from 
hematopoietic stem cells [107-108]. There are subsections of leukocytes known as granulocytes, 
antigen presenting cells and lymphocytes. Here, I will mainly focus on cells involved with the 
innate immune system –specifically antigen presenting cells (APCs) and granulocytes. APCs 
include macrophages and dendritic cells, which coordinate their arrival at specific sites of trauma 
[109-110]. These phagocytes have the general role of the detection of foreign invaders or their 
particles –including carbohydrates, proteins and lipids –and literally presenting or ‘showing’ 
chopped up pieces of pathogens (antigens) to activate a lymphocyte (adaptive immune cells such 
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as T and B cells) [111-112]. How can these innate immune cells, specifically phagocytes, know 
that what they are presenting is a cause of danger to the host? The answer to this question lies in 
a host of proteins capable of detecting pathogen components not found in the human body. 
Pathogen Associated Molecules. Foreign molecular components of a microorganism can 
come in all shapes and sizes and are usually referred to as pathogen associated molecular 
patterns, or PAMPs. PAMPs are molecules found in the pathogen, but not in the host, like cell 
wall components or specific pathogen proteins [113-116].  
PAMPs of IAV. The pathogenic particles that trigger innate immunity in response to IAV 
include the following: host DNA released in response to death of neighboring cell by IAV, 
ssRNA and dsRNA from the virus, the virus M2 protein, viral PB1-F2 protein and the associated 
damage to the cell in response to viral replication all serve to activate the immune response [117-
119].  
PAMPs of Aspergillus fumigatus. Research in A. fumigatus virulence is currently a topic 
of interest due to its complexity described above. Several well-defined PAMPs of A. fumigatus 
include the carbohydrates present within the cell wall, specifically -1,3-glucan, mannose-
containing structures such as galactomannan, and chitins [120-122].  
Pathogen Detectors. Interestingly, there exist specific immune receptors called pattern 
recognition receptors (PRRs) present in or on the host epithelial and immune cells that can 
distinguish foreign molecular markers or PAMPs and host cell damage associated molecular 
patterns (DAMPs), like extracellular ATP release. The specificity of PAMPs and DAMPs and 
their activation of exclusive PRRs remains dependent upon the pathogen causing the infection. In 
other words, IAV will activate a specific subset of PRRs that are different than the PRRs 
activated by A. fumigatus. There are a variety of PRRs such as Toll-like rectors (TLRs), retinoic 
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acid-inducible gene-I (RIG-I)-like receptors (RLRs), nucleotide oligomerization domain (NOD)-
like receptors (NLRs), C-type lectin receptors (CLRs) and absent-in-melanoma 2 (AIM2)-like 
receptors. Once these PRRs are activated by PAMPs and/or DAMPs, cellular signaling cascades 
within these cells result in phagocytosis, transcription of immune genes, activation of 
multiprotein complexes known as inflammasomes and the production of immune signaling 
molecules or cytokines [123-127].  
PRRs and IAV. During IAV infection and genome replication, the 5’ triphosphate (PPP) 
of uncapped-RNA is bound by a specific cytoplasmic sensor, RIG-I of the RLR family. 5’ 
triphosphate containing RNA is not usually present in the cytoplasm of human cells. Human 
mRNA possesses a 5-methyguanidine cap added during maturation, while tRNA and rRNA only 
have 5’ monophosphates. Thus, viral RNA with a 5’ triphosphate indicates to the cell that 
something is amiss. Deficiency in RIG-I is linked to an impaired antiviral response. Activated 
RIG-I interacts with a downstream adaptor protein, the mitochondrial antiviral-signaling protein 
(MAVS) [128-131]. Prior research has linked diminished levels of interferon production to a 
deficiency in MAVS causing increased difficulty fighting viral infections within Mavs 
knockdown mice [132]. TLRs are also utilized to recognize IAV, specifically TLR3, TLR7 and 
TLR8. These receptors of viral RNA reside in the endosome where they can sense any RNA that 
does not escape the endosome during viral infection. Activation of TLR3, 7, and 8 subsequently 
signals the adaptor proteins TIR-domain-containing adapter-inducing interferon-β (TRIF) and 
myeloid differentiation primary response gene 88 (MYD88) [133-136]. Whether it is the RIG-I – 
MAVS or the TLR – TRIF/MYD88 pathway, detection of viral RNA induces the production of 
pro-inflammatory cytokines and type I interferons [137]. 
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PRRs and Aspergillus fumigatus. Of the PRR families, previous research has proved that 
A. fumigatus can activate CLRs, TLRs and various NLRs [138]. The best-characterized PRR 
activated via A. fumigatus is the CLR dectin-1 through the recognition of -1,3-glucan moieties 
present on germinating or swollen conidia. Another CLR, dectin-2, can recognize the -mannans 
such as galactomannan. The recently discovered -mannans, constituents of the outer layer of 
the fungal cell wall, are responsible for masking -glucans. There remains the possibility that 
once the conidia are inhaled by the host, the detection of conidia by dectin-2 precedes dectin-1 
[139]. TLRs 2 and 4, located on the extracellular surface of the host cell, were shown in several 
studies to be key recognition PRRs of the host against A. fumigatus. However, their functions 
currently have not been fully elucidated due to conflicting reports. Presumably, TLR 2 detects 
chitin and TLR 4 detects -glucans. After Dectin-1 binds to fungal -1,3-glucans, adaptor 
proteins, like caspase recruitment domain protein 9 (CARD9), and kinases, like spleen tyrosine 
kinase (Syk), ultimately result in the activation of similar signaling pathways that were discussed 
for TLRs, namely MYD88. For sake of simplicity, the cascade of activation and signaling 
initiates the transcription of pro-inflammatory genes, like cytokines, and genes required for 
cytokine maturation. [140-141]. 
Transcriptional Activation. The discussed adaptor proteins for PRR signaling involved in 
both IAV and A. fumigatus infections – MYD88, TRIF, MAVS and CARD9 - all mediate the 
downstream activation of one common family of transcription factors known as nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-B). PRRs and adaptor proteins regulate 
this family of five transcription factors. However, antigen receptors like PRRs are not the only 
means by which the NF-B pathway is activated. Oxidative stress and the production and 
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sensing of cytokines by neighboring cells facilitate its activation too. NF-B proteins have the 
ability to form distinct transcriptionally active homo- and heterodimeric complexes [142-143].  
NF-B signaling. The most recognized dimer of the NF-B family is RelA (p65)/p50. 
The p65/p50 dimer in most unstimulated cells remains within the cytosol inactivated by a family 
of inhibitors known as IB proteins (//). When PRRs and adaptor proteins interact, like RIG-
I – MAVS, this triggers a kinase cascade leading to activation of the p65/p50 dimer via 
phosphorylation of the serine residues of IB by the IB kinase (IKK) complex. Phosphorylation 
of IB results in polyubiquitination at two lysine residues, 21 and 22 (Lys21/Lys22) [144-148]. 
Ubiquitination is a type of post-translational modification where ubiquitin proteins are used as a 
‘tag’ to mark the specific protein for degradation via the proteasome complex [149-152]. 
Polyubiquitination of IBs are recognized by the multi-subunit 26S proteasome, where they are 
unfolded and degraded into small peptides to be recycled. This 26S proteasome degradation 
process releases NF-B dimers, which translocate into the nucleus. These NF-B dimers bind to 
promoters of inflammatory or immune-related genes through B motif interactions. NF-B is a 
crucial mediator of pro-inflammatory gene induction. If the activation of downstream adaptor 
proteins and PRRs ceases, so will the transcription of pro-inflammatory associated gene 
expression [153-157]. Negative feed-back loops operate as check-points to excessive 
inflammation and the diseased states that could result from excessive inflammatory conditions 
[158-160].  
Interferon Production. Interferons are important antiviral cytokines produced by innate 
immune cells to communicate the presence of a viral infection and initiate cellular responses to 
block virus replication [161]. To accomplish this, MAVS activates downstream antiviral 
signaling pathways through interferon regulator factors (IRFs), which are crucial for the 
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expression of type I interferons (specifically IFN-α and IFN-β) [162-164]. Endosomal TLR also 
induce the transcription of type I interferons through this method. Specifically, TLR receptor 
signaling and their activated adaptors results in IRF3 and IRF7 activation. IRF3 and 7 are 
transcription factors that induce expression of type I IFNs [165-166]. Once the interferons are 
made, they are released from the cell and bind in both paracrine and autocrine fashion to the 
IFN-α receptor (IFNAR) [167]. This canonical signaling pathway of type I IFNs activates the 
receptor-associated protein tyrosine kinases Janus kinase I (JAK1) and tyrosine kinase 2 (Tyk2). 
These two receptor-associated proteins facilitate the phosphorylation mediated activation of 
STAT1 and STAT2 (signal transducer and activator of transcription 1 and 2). STAT1 and 
STAT2 dimerize together and rapidly translocate to the nucleus. Once inside the nucleus, they 
bind with IFN-regulatory factor 9 (IRF9) to form a complex known as IFN-stimulated gene 
factor 3 (ISGF3) [168-170]. ISGF3 is a transcription factor complex that induces specific 
antiviral gene expression, like Mx1, that inhibits IAV RNA replication [171].  
Cytokines. Immune signaling molecules called cytokines are cellular biochemicals 
released and sensed by cells to permit cells to communicate with each other [172]. Because of 
the significance of NF-B within this investigation, I will use it as the primary example of a 
family of transcription factors that regulates the production of cytokines. NF-B induces 
transcription of proinflammatory pyrogenic cytokines namely interleukin-6 (IL-6), tumor 
necrosis factor- (TNF-) and interleukin-1-beta (IL-1β) [173-174]. IL-1β is also a mediator in 
the regulation and production of TNF-and IL-6. IL-1β has attracted considerable scientific 
attention in many diseased states due to its manifestation of innate immunity through 
inflammation. Usually, this cytokine functions in host defense, but when it is uncontrolled, its 
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continued expression is detrimental to survival. Activation of specific inflammasomes aids in the 
processing and secretion of IL-1β [175-176].  
Inflammasome Activation. Of the variety of inflammasomes, here only the two closely 
related to our study will be discussed, the NLR Family Pyrin Domain Containing 3 (NLRP3) and 
Absent in melanoma 2 (AIM2) inflammasomes. Simply put, inflammasomes are caspase-
activating molecular machines.  
The NLRP3 inflammasome. Anatomically, the best characterized inflammasome, NLRP3, 
once activated, is constructed of the following protein: NLRP3 binds to an adaptor protein 
known as ASC (apoptosis-associated speck-like protein containing a CARD), which in turn 
binds pro-caspase-1 [177-179]. Caspase-1 is a protease. The integration of pro-caspase-1 allows 
the multiprotein complex to cleave itself, and cleaved caspase-1 is fully functional with the 
ability to cleave cytokines such as inactive pro-IL-1β into mature functional IL-1β, thereby 
inducing inflammation [180-181]. Active caspase-1 also cleaves and activates Gasdermin D, 
which is a membrane pore forming protein, causing a version of cell death known as pyroptosis. 
The NLRP3 inflammasome requires a two-step activation process. First, PAMPs activate TLRs 
resulting in increased expression of NLRP3 and pro-IL-1β. Second, DAMPs or PAMPs, such as 
potassium efflux, lysosomal-damage, uric acid, silica, aluminum, whole pathogens, 
mitochondrial damage, cholesterol crystals and amyloid-β induce a conformational change 
and/or post-translational modifications of NLRP3, which results in its activation and binding to 
ASC [182-184]. A non-canonical method of activation is also perpetuated through the binding of 
LPS in the cytoplasm of cells to another caspase, caspase-11. Active caspase-11 then facilitates 
the activation of the NLRP3 inflammasome complex. Both the canonical and non-canonical 
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methods of activation lead to inflammasome complex assembly and activation of caspase-1 with 
cell death and inflammation as the final consequences [185-188].  
The AIM2 inflammasome. The AIM2 inflammasome is a cytoplasmic sensor of double-
stranded DNA molecules of self and foreign (pathogens) origin [189-191]. AIM2 has two 
domains that structurally define it: one HIN domain and one pyrin domain (PYD). The HIN 
domain of this specific ALR recognizes dsDNA. The HIN domain can have several distinct sub-
classes: HIN-A, HIN-B and HIN-C [192-195]. Of these sub-classes, previous research has 
proposed that they may differ in function due to minor differences in structure, therefore they 
may bind DNA at different affinities. AIM2 also forms an inflammasome capable of activating 
IL-1β and inducing pyroptosis through the cleavage of caspase-1 [196-197].  
Caspase-1. Caspase-1 is one of the many inflammatory cysteine-aspartic proteases 
characterized in mammals (specifically mice and humans). Caspases begin as inactive zymogens 
(pro-caspases) that can be activated through cleavage following activation by a suitable stimulus 
[198-199]. This activation is based not only on proximity to other caspase molecules, but also 
affected by post-translational modifications. The inflammatory caspases, like caspase-1, are 
termed ‘inflammatory’ because they activate substrates like pro-IL-1β and cause cell death in a 
manner that releases cytosolic contents that potentiate inflammation [200-202].  
As already revealed, biologically active IL-1β is a pleiotropic cytokine that influences 
multiple cell types to enable inflammation. Without inflammasomes activating IL-1β, the 
intensity of inflammatory responses would diminish. Therefore, excessive or inappropriate 
inflammatory responses could be controlled or remediated by inhibiting the inflammasome 
[203].   
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Pathogen Immune Evasion. The evolutionary arms race between pathogen and host is 
an enduring battle. Due to the selective pressure imposed by the immune system, pathogens such 
as IAV and A. fumigatus constantly evolve and have established an assortment of techniques to 
evade the immune system.  
Influenza A virus. IAV, although very small and simple, contains a collection of elegant 
mechanisms to evade the immune system; it is a master tactician. Beginning with NS1 protein 
expression, IAV can inhibit the cascade needed in the initial production of type I IFN production, 
thereby acting as an effective suppressor of host antiviral immunity [204]. By doing this, IAV 
sets itself up for mass replication events, therefore spreading the virus throughout the current 
host and impairing the quality of the upcoming adaptive immune response. NS1 inhibits RIG-I-
mediated signaling through halting ubiquitination, therefore preventing the production of type I 
IFNs [205-206]. PB1-F2 has been shown to boost mitochondrial ROS and calcium efflux 
through the inhibition of MAVS [207-209]. PB2 and PA together cap-snatch. Cap-snatching is 
the process that IAV does to ‘steal’ the cap off host mRNA by cleavage of the 5’-methyl 
guanidine cap of host mRNA and transferring it to viral mRNA. This stolen host cap is then used 
as a primer to begin transcription of viral mRNAs and to make the viral mRNA undetectable by 
RIG-I [210].  
IAV and phagocytosis impairment. IAV infection primes the hosts airways for 
co/secondary infections [211-213]. With understood bacterial co-infections, such as with S. 
pneumoniae, the respiratory impairments are well characterized [215-216]. These published data 
have shown that influenza infections result in increased and prolonged bacterial growth and a 
reduced ability of macrophages to effectively clear bacteria due to reduced phagocytic activity 
[217-219]. This reduction in the ability of macrophages to effectively phagocytize pathogens 
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during IAV infections is quite common –proven now even in fungal infections! Oliveira et al. 
determined that IAV at the peak of infection, around day 3 in their established murine model, 
causes an impairment of phagocytosis of yeast-like fungus, Cryptococcus gattii. This host-
vulnerability factor is also demonstrated previously in cases of bacterial co-infections too [220-
223]. Phagocytosis must occur rapidly in order to halt dying cells from exposing damage 
associated molecular patterns, or DAMPs and prevent excessive inflammation [224-225]. 
Macrophage activity during IAV infection is suppressed through inhibitory receptors like 
CD200, disruption of normal ciliary clearance in the lung and by decreasing concentrations of T 
cell-derived interferon (IFN-) through type 1 interferon production (IFN-/) [226-227]. 
Perhaps not only bacterial clearance is affected by this. Perhaps fungal pathogens could take 
advantage of these diminished phagocytic responses as well? This hypothesis is supported by 
research into heritable genetic defects that demonstrate deadly fungal infections are mediated by 
macrophage activation defects, along with intact T-cell activation therefore leading to reduced 
macrophage fungicidal activity [228-230].  
Aspergillus fumigatus. Usually, the innate immune system eliminates A. fumigatus 
through the coordination action of alveolar macrophages, neutrophils and NK cells. These cells 
help to kill conidia in the lungs. In addition, the pseudostratified columnar epithelium integrated 
with goblet (mucus producing) and ciliated cells creates a mucus barrier that is constantly being 
swept up and out of the airways to prevent colonization of the lungs [231-232]. However, if there 
is significant impairment of the immune system through corticosteroid use, AIDS, 
immunosuppressive medication, genetic abnormalities or, as I hypothesize, acute IAV infections, 
A. fumigatus can effectively infiltrate and infect the host. A. fumigatus can be shielded so that the 
fungus can evade the immune system. For example, the surface of A. fumigatus conidia consists 
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of coats of melanin and hydrophobin to literally act as a shield to protect PAMPs from 
recognition by PRRs. Melanin not only envelopes the conidial cell wall to protect the conidia 
from oxidative stress and desiccation, but it also aids in preventing phagocytes from engulfing 
and killing A. fumigatus conidia through inhibition of a specific form of phagocytosis termed 
LAP [239-242]. When conidia germinate, they shed the surface layers of melanin and 
hydrophobin and expose PAMPs such as -1,3-glucans. Other fungal proteins, including GAG, 
gliotoxin and fumagillin (toxins), have evolved to poison host cells and prompt apoptosis. GAG 
also specifically inhibits a mechanism employed by neutrophils called neutrophil extracellular 
traps or NETs and it can inhibit IL-1α/β signaling [233-238]. 
A. fumigatus, Autophagy and DAPK1. Autophagy is an elaborate cellular self-eating 
process essentially conserved to allow the degradation and recycling of really anything the cell 
wants to dispose of. Simply, both forms of autophagy –canonical and non-canonical- result in 
formation of a double-membrane structure containing the sequestered cytoplasmic material (also 
called the autophagosome) [243-245]. Ultimately, fusion of the autophagosome with a lysosome 
is permitted by Rab and SNARE proteins. Rab proteins, specifically Rab7, interact with tethering 
factors, and Q-SNARE STX17. Together, they allow the fusion events of the autophagosome 
with lysosomes, resulting in the autophagolysosome [246-250]. The canonical pathway of 
autophagy involves four steps: initiation (mediated by the ULK1 complexes), nucleation 
(BECLIN1-PtdIns3KC3-ATG14L complexes), elongation and closure (ATG12-ATG5 and LC3-
PE conjugation systems) [251-252]. In regard to infections with A. fumigatus, I will focus on 
LC3-associated phagocytosis (lapidated microtubule-associated protein 1 light chain 3(LC3)-
associated phagocytosis or LAP). This specialized form of autophagy links PRR signaling with 
phagosome development, inflammation and host defenses [253-254]. Observed as 
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mechanistically distinct in comparison to canonical autophagy, LAP is regulated by the protein 
Rubicon, which actually inhibits canonical autophagy. This inhibition of canonical autophagy is 
due to the formation of the Atg14L-containing Beclin-1/VPS34Class III PI3K complex. Rubicon 
activates LAP through association with a unique UVRAG-containing Beclini-1/VPS34Class III 
PI3K complex on the phagosome [255-256]. Fundamental requirements of LAPosome formation 
occur through PI3P (phosphoinositol-3-phosphate –a lipid) and reactive oxygen species (ROS) 
production. Rubicon facilitates the process of LAPosome formation by activation of class III 
PI3K and stabilization of NADPH-complex formation through the connection of the p22phox 
subunit, which is required for ROS production. LAP recently has surfaced as an integral anti-
inflammatory pathway and contributes to host defense against extracellular pathogens, including 
A. fumigatus through recognition of -glucans through Dectin-1 [256-259]. Therefore, 
experiencing a defect in LAP would cause phagocytes to experience impeded killing 
mechanisms and increased susceptibility for A. fumigatus infections. In an effort to determine the 
molecular mechanisms responsible for anti-inflammatory responses upon activation of LAP, 
researchers identified IFN- mediated expression of death-associated protein kinase 1 (DAPK1) 
signaling as a promising role in the control of A. fumigatus infections [260-261]. DAPK1, a 
calmodulin-regulated serine-threonine kinase, is also a Janus molecule that is regulated by 
JAK/STAT-independent IFN- signaling. It seems that DAPK1 associates with A. fumigatus 
LAPosomes and then induces proteasomal degradation of NLRP3 via ubiquitination of NLRP3 
by FBXL2. When NLRP3 is degraded, the immune response is muted, and overt inflammation is 
avoided. This flourishing area of research holds much promise in the application of fungal 
immunology [262-263].  
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IAV and A. fumigatus Co-infections 
Co-infections, by common definition, occur when two or more pathogens simultaneously 
infect a host [264]. Co-infections begin with a primary pathogen, here it is IAV. IAV 
successfully infiltrates the host and distracts or depletes the host’s array of immune defenses. 
This is optimal for an opportunistic pathogen, such as A. fumigatus, to infect the same host. Co-
infections with IAV and A. fumigatus are becoming more prevalent, or at least more recognized. 
It is believed that, in general, an inappropriate immune response through excessive inflammation 
from a cytokine storm results in the rising rates of morbidity and mortality seen with IAV and A. 
fumigatus co-infections [265].  
Clinical case reports. Since the 2009 H1N1 Pandemic, there has been an increasing 
awareness about influenza-associated-aspergillosis (IAA) and the propensity that IAV has to 
predispose patients to secondary fungal infections more than previous IAV strains. There exists 
limited understanding about the consequences of fungal infections with IAV. Patients who 
experience severe influenza A are increasingly susceptible to more severe pneumonia [266-272]. 
Dr. Mitsuru Toda and her team from the US Centers for Disease Control and Prevention (CDC) 
Mycotic Diseases Branch recently shared results of a study they presented at ID Week 2018 
analyzing cases of invasive aspergillosis as a risk factor for patients with current influenza. What 
they found was prominent –greater than one-third of patients documented with IAV-Aspergillus 
co-infections lacked immunosuppressive conditions, like AIDS, that are typically associated with 
invasive aspergillosis [273]. This indicates that previously healthy people are developing 
invasive aspergillosis after even mild infections with influenza. Before Dr. Toda’s findings that 
more than one-third of the 57 cases in the USA did not have a documented immunosuppressive 
condition, published clinical case reports were sporadic. The sporadic nature of individual case 
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reports made it difficult to determine the significance of IAA, especially among previously 
immunocompetent hosts. Of the documented 57 cases in the literature, 92.9% of the cases were 
associated with IAV. Of those, 82.33% were due to the H1N1 subtype. It must be noted here that 
since 2010, the majority of cases of IAA were due to H1N1 [273]. 
To further extend the awareness, van der Veerdonk and colleagues observed similar 
trends in the UK. An analysis of 68 IAA cases reported in the literature before 2005 
demonstrated the mortality rate was 47%. IAA in critically ill patients with influenza during the 
flu season in the Netherlands from December 2015 to April 2016 reported IAA cases had a 
significantly higher rate of up to 61%, and this was despite antiviral and antifungal therapies. 
This mortality rate among affected patients without traditional risk factors of invasive 
aspergillosis was not lower compared to patients with known low, intermediate, or high risk for 
an invasive fungal disease state. It seems that the use of corticosteroids might not be as strong as 
a predisposing factor contributing to IAA illness as alleged previously [274-276]. Another 
extraordinary observation in these documented IAA infections in immunocompetent individuals 
is that their age ranged from roughly 20 to 80 years old. This also eliminates another 
preconceived predisposing factor –age—which is associated with lower immune function in the 
very young and very old [277].  
The reasons for the intense rise in the number of recently published cases of IAA is 
currently unclear. Hypotheses from the scientific community on this topic range from the 
evolution of more virulent IAV strains (exemplified by 2009 H1N1 pandemic strain), the 
observed severity of damage to respiratory mucosa reported possibly allowing for increased 
fungal invasion, and generally greater reporting over time. Exposure to A. fumigatus at a critical 
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time of both reduced mucosal and systemic immune defenses could also lead to the observed 
diseased state [278], but it is not clear why exposure to A. fumigatus has increased. 
 
Problem Statements and Hypotheses 
In order to understand IAA, the virus, fungus and host must be examined. Similarly, any 
model to study IAA must include all players. Previously, research has focused on each pathogen 
and the host response separately. Collaboration with medical mycologists, virologists and 
immunologists could aid in the exploration of crucial immune pathways utilized by viral and 
fungal pathogens to successfully invade tissue and evade the host’s immune system. My 
scientific study here will bring increased awareness of IAA as an early complication of IAV 
infections through the knowledge provided through investigating a novel model of IAV-A. 
fumigatus co-infection. As a result, hopefully, more awareness, prompt diagnoses and initiation 
of suitable treatments can be implemented in future seasonal flu outbreaks.  
I discovered through preliminary experiments that co-infections of macrophages with 
IAV and A. fumigatus results in an immense increase in the production of pro-inflammatory 
cytokines (IL-1β, TNF-, IL-6) and active caspase-1-p20 in comparison to IAV and A. fumigatus 
alone.  
Problem Statements. There are two major roadblocks to furthering our understanding of 
IAA: a lack of an animal model for in vivo studies, and a lack of understanding of the immune 
response and how this and other factors may contribute to IAA. The objective of my research 
was to determine the cause of the increase in pro-inflammatory cytokine levels during an IAV 
and A. fumigatus co-infection and to effectively recapitulate this co-infection within a murine 
model. Previously, researchers were able to generate a different model IAV-fungal co-infection 
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with Cryptococcus neoformans and C. gattii. Their investigation showed that acute IAV 
infection predisposes mice to C. neoformans and C. gattii infections, with the highest morbidity 
and mortality rates occurring if mice were co-infected with the fungus on day 3 after IAV [220].  
Based on our preliminary research and the IAV- C. neoformans/gattii mouse model, I 
narrowed down our research to two testable and answerable questions:  
 In vivo 
o What variables are required for development of a co-infection model in 
mice? Specifically, what doses of IAV and A. fumigatus and how many 
days apart should the infections be to induce the highest morbidity and 
mortality of mice? 
 In vitro  
o Why is there an enhanced activation of caspase-1-p20 and cytokines 
during IAV-A. fumigatus co-infections and does this cause the high 
morbidity and mortality in humans? 
Hypotheses. Through the establishment of working in vitro and in vivo models, I propose 
the following two hypotheses to explain the preliminary observations of enhanced pro-
inflammatory cytokine production, caspase-1 activation and high morbidity and mortality rates 
seen in humans with IAA: 
 In vivo 
o If IAV predisposes humans or mice to A. fumigatus infection, then 
infecting mice with IAV should allow for infection with A. fumigatus (it 
does not normally infect mice even at very high doses), and IAV infection 
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coupled with A. fumigatus infection should result in more severe disease 
than either infection alone.  
 In vitro 
o If caspase-1 activation is increased during co-infection compared to single 
infection with IAV or A. fumigatus, then factors regulating activation of 
AIM2 and NLRP3 must be enhanced, including AIM2 and NLRP3 gene 
expression and activation signals like ROS.  
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MATERIALS AND METHODS 
 
In order to carefully elucidate immune signaling as a whole during infections, the use of 
models to simulate infections in humans within a model organism or cell line is preferable. IAV 
and A. fumigatus co-infections were recapitulated in both in vitro and in vivo models in this 
research. Figure 1, a visual representation of the complexity of IAV and A. fumgiatus co-
infections and where the science led me during my thesis project. 
 
Overall Experimental Designs 
The experiments in mice and cell culture were performed with a mouse adapted strain of 
IAV – influenza A/PR/8/34 H1N1 virus and Type 293 A. fumigatus (ATCC MYA-4609). Mice 
were infected with various concentrations of IAV and A. fumigatus alone or co-infected with 
both pathogens on various days and monitored for symptoms of morbidity (weight loss) and their 
mortality. Cell cultures of mouse-derived macrophages were also infected with IAV and A. 
fumigatus alone or co-infected with both pathogens. Cell culture samples were collected to check 
cytokine and associated protein and gene production through activation. Specifically, analyzation 
of the signaling proteins with the predicted pathogen recognition receptor pathways that could be 
involved. Lastly, data normalization and statistical analysis of these forms of data were 
completed using Microsoft Excel and GraphPad Prism Version 7.0. 
 
Animal Welfare 
 All mice used in these experiments were of the pathogen-free mice (Mus musculus) 
C57Bl/6 genetic background including knockouts of Nlrp3-/- and Aim2-/- originated from The 
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Jackson Laboratory and bread in-house within Missouri State’s vivarium.  All breeding, 
experimentation, and data collection were performed in accordance to the Institutional Animal 
Care and Use Committee (IACUC) –specific accepted protocols utilized for living mouse and 
cell culture experiments were February 17, 2016; approval #16.015 with continuation on 
February 19, 2019 (Appendix A) and July 26, 2018; approval #2018-07 (Appendix B), the 
AVMA Guidelines on Euthanasia, NIH regulation (Guide for the Care and Use of Laboratory 
Animals), and the U.S. Animal Welfare Act of 1966 (Appendix A).  
 
Preparation of fungal and viral stocks 
 Viral and fungal infectious agents utilized received prior approval for this product was 
obtained from the Institutional Biosafety Committee (IBC) on (October 23rd, 2015) (Appendix 
B). Both pathogens were grown and used within the laboratory.  
 Preparing an A. fumigatus stock. A. fumigatus used in this study was a laboratory 
pathogenic species, gifted from Dr. Thirumala-Devi Kannetganti, St. Jude Children’s Research 
Hospital. Sabouraud Dextrose Agar (better known as ‘SabDex’ or SDA) was made per 
manufacture (ThermoFisher Scentific, catalog #CM0041R) recommendations. The agar was 
poured into T175 cm2 tissue culture flasks (ThermoFisher Scientific) and cooled cap-off inside a 
sterilized certified biosafety cabinet. Five-hundred L of A. fumigatus conidia in glycerol stock 
(Af293, ATCC MYA-4609) was pipetted into the flasks with cooled agar and incubated at 
37C/5% CO2 for approximately 7 to 14 days or until the fungus was thick and black in color. 
The live asexual spores of A. fumigatus were harvested within a certified sterilized biosafety 
cabinet by pouring approximately 10 mL of sterile 1X Phosphate Buffered Saline (PBS) 
(prepared from 10X ThermoFisher Scientifc PBS, pH 7.4, RNase-free, catalog#AM9625) to each 
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tissue culture flask filled with thick black fungus. The flasks were re-capped and shaken 
vigorously to suspend spores in the PBS. The PBS-spore mixtures from both flasks were pooled 
together into one 50 mL centrifuge tube. Tween 80 was supplemented to the falcon tube with the 
PBS and spores at a total concentration of 0.1% v/v of Tween 80 (Sigma-Aldrich, CAS#9005-
65-6) The Tween 80 was used to reduce surface tension between spores and water to aid in the 
precipitation of spores out of the PBS-spore mixture. The spore mixture was centrifuged at 2000 
rpm for 10 minutes. The supernatant (PBS) was decanted as bio-hazard waste and 5 mL of 50% 
glycerol (Sigma-Aldrich, CAS#56-81-5) in Brain Heart Infusion (BHI) broth (prepared 
according to the manufacture, Sigma-Aldrich, CAS#53286) was added to the concentrated A. 
fumigatus spores. Next, the fungal stock was aliquoted in low temperature cryovials at 500 L 
and frozen at -80C.  
 Determining Fungal Stock Concentration via CFUs. Approximately 25 mL of SDA was 
poured per plate into 10 petri dishes to eventually determine colony forming units (CFUs) of the 
spore stock through a CFU assay. The agar was kept at room temperature until solidified into a 
sterilized biosafety cabinet. Ten-fold fungal serial dilutions of the stock were performed with 900 
L of PBS and 100 L of fungal stock prepared previously. Then, 100 L of each dilution, from 
10-1 to 10-7, were dispensed onto each plate as one-drop on each SDA plate (1 plate per dilution), 
liquid was spread and plate incubated upside down at 37 C/5% CO2 for 24 to 48 hours or longer 
–until there were visible fungal colonies to count. Once colonies were determined ready by 
inspection, they were counted visually. The dilution with colonies within a range of 30-300 was 
selected to perform a back-dilution calculation to obtain the CFU/mL. 
Preparing viral stocks. To prepare viral stocks, two methods were utilized to grow and 
purify the stock – these include growth of the IAV strain A/Puerto Rico/08/1934 (H1N1) 
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(hereafter referred to as ‘PR8’) via chicken eggs and MDCK cells. Following growth and 
aliquoting of the PR8, the concentration of the virus was determined through plaque forming 
units (PFUs) generated from a viral plaque assay technique, which will also be explained below.  
 Growing an IAV Stock in Chicken Eggs. Fertilized chicken eggs were provided by a 
local chicken breeder. The eggs were incubated in a humidified 37.5C incubator and flipped 
twice a day for 10 to 12 days (or until the candled eggs showed a viable chick: dark shadow 
within the egg with blood vessels, movement, and an intact air sac). Viable eggs were infected 
inside a sterilized certified biosafety cabinet. Eggs were first decontaminated by spraying 70% 
ethanol on the exterior of the egg shell. Then, a hole was made about 1cm above the air sac line 
with a sterile 18-gauge needle. Next, using a 1 mL insulin syringe and a 1inch 22-gauge needle, 
100L of virus solution diluted to 104 PFU, was injected into each egg at a 45-degree angle 
through the previously made hole. Super glue was used to patch the hole and the developing eggs 
were stored again in a humidified incubator at 37.5C and flipped twice a day for 72 hours.  
 After 72 hours, the eggs were pulled from the incubator and visualized with a flashlight 
to check viability of the developing chick embryo. If the chick inside the egg was still alive, 
indicated by movement of the chick, the eggs were placed inside a 4C refrigerator for at least 1 
hour to stop the heart and blood flow of the developing chick. After 1 hour, the eggs were placed 
inside a sterilized certified biosafety cabinet and sanitized with 70% ethanol to prevent any 
contamination from the shell to the fluid within the egg containing the influenza A virus. Using 
sanitized forceps, the shell of the eggs was chipped away over the air sac. The allantoic 
membrane was pealed aside and the clear allantoic fluid was pipetted into sterile 50 mL 
centrifuge tubes. These tubes were kept on ice and spun down at 4,000 x g for 10 minutes at 4C 
to pellet unwanted debris. The clear supernatant from the tubes was transferred into new 50 mL 
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tubes and kept on ice. The clarified allantoic fluid (supernatant) containing the influenza A virus 
was then aliquoted and stored at -80˚C for further use. The debris-pellet and eggs were disposed 
in a BSL-2 waste container. 
 Growing an IAV Stock in MDCK Cells and Purification via Ultracentrifugation. 
Alternative methods of virus stock preparation were utilized in hopes of increasing stock 
concentrations and making a larger amount of a stock. Madin-Darby Canine Kidney (MDCK) 
cells (a gift from Dr. Paul Thomas, St. Jude Children’s Research Hospital) were grown until 
confluent (about 3 days) within a T175 tissue culture flask. The MDCK cells were washed twice 
with PBS and infected with PR8 at a concentration of 2.5 x 106 PFU diluted in 5 mL of 1X 
plaque assay media per T175 flask. These PR8 infected flasks were incubated at 37 C/5% CO2 
for one hour with intermittent shaking every 10 minutes. After the 1-hour incubation, the PR8-
containing 1X plaque media was removed from the infected flasks and an additional 20 mL of 
1X plaque media was pipetted into each flask. To allow the virions of PR8 to mature, 20 L of 
TPCK trypsin was aliquoted into each infected flask. The infected flasks were stored again at 
37C/5% CO2 for approximately 72 hours or until 85% of the cells were dead. The virus-laden 
1X plaque media was transferred from the infected flask to 50 mL centrifuge tubes and vortexed 
for 5 minutes to detach any virions from cells and put them into the media. These now vortexed 
tubes were centrifuged at 2,000x g for 10 minutes to pellet out the MDCK cells. Ultra-centrifuge 
tubes were preloaded with 3 mL of 5% sucrose in MHN buffer (Table 1). The virus-laden media 
was gently overlaid atop the sucrose buffer.  Tubes were ultra-centrifuged in a JS-24 rotor at 4C 
at 23,000 rpm for 1 hour. Tubes were places on ice in the biosafety cabinet and all but 
approximately 3 mL of supernatant was removed from each tube, leaving the virus pellet. The 
remaining 3 mL of media from each tube was pooled together into one ultra-centrifuge tube and 
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ultra-centrifuged again at the same conditions previously described. Once ultra-centrifugation 
was completed a second time, all but 3 mL of supernatant was again carefully removed. The 
remaining 3 mL of media and the virus pellet were transferred to and vortexed in a 15 mL 
centrifuge tube for 10 minutes to resuspend the virus pellet into solution. The virus stock was 
aliquoted at approximately 30 L for each 1.5 mL tube and stored at -80C until use.  
 Determining Viral Stock Concentration via Plaque Assay. In order to obtain the 
approximate number of infectious virions in a sample, the plaque assay technique was utilized. 
Approximately 48 hours before beginning the plaque assay for IAV, MDCK cells were seeded in 
12-well culture plates at 3 x 105 cells/well within 1 mL of 1X DMEM +10% FBS + 1% 
Pen/Strep. On the day of the plaque assay, ten-fold dilutions of the viral stocks (grown in eggs or 
concentrated by ultracentrifugation) were prepared in 1X plaque assay medium (See Table 2). 
Next, MDCK cells were washed twice with about 1 mL of 1X PBS per well each time. Then, 
100 L/well of the virus dilutions were added to duplicate wells within the 12-well plates. These 
plates were incubated at 37C/5% CO2 for 1 hour with intermittent shaking every 10 minutes (to 
spread the media containing the diluted virions across the cells and to prevent the cells from 
drying). During the last 20 minutes of plate incubation (40 minutes into the hour incubation 
period), the agarose overlay was prepared: 2% SeaPlaque low melting point agarose (Bio 
Whittaker, catalog #50100) in diH2O was microwaved, cooled to a temperature around 37 to 
42C and was mixed together with pre-warmed (37 to 42C) 2X plaque assay medium (Table 3) 
at a 1:1 ratio. TPCK-trypsin was added to the overlay mixture at a final concentration of 1.0 
g/mL. Following the 1-hour incubation, the infection medium was aspirated from each well and 
2 mL of the warm agar/plaque medium overlay was added to each well. The agar was allowed to 
harden completely within the biosafety cabinet with lids ajar on the plates (to prevent unwanted 
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condensation) before flipping the infected plates over and incubating them at 37C/5% CO2 for 
72 hours. After 3 days, the agar plugs were scooped out of the wells and plates stained with 1% 
crystal violet in methanol. The stain was incubated at room temperature within the biosafety 
cabinet for around 30 seconds to 1 minute and was removed. The wells were then rinsed twice 
with water. After drying upside on paper towels, the plaques were read by counting clearings 
visually observed in the wells.  
 
In vivo Infection Schemes 
 In order to understand the causes and contributing factors associated with human case-
study-based morbidity and mortality, I sought to develop a moue model using the C57Bl/6J 
mouse strain. To effectively do this, an in vivo method was created from previous work with 
another misunderstood viral-fungal co-infection, IAV and C. neoformans and C. gatii [220]. At 
least eight-week old mice were anesthetized on day 0 by intraperitoneal injection with 80 mg/kg 
Ketamine and 8 mg/kg Xylazine diluted in 1X PBS. Mice were infected with approximately 250 
to 300 PFU of PR8 intranasally in a volume of 30 L of 1X PBS. Mice were mock infected, 
single infected with PR8 or A. fumigatus or co-infected depending on their assigned groups on 
days 3, 5 and 7 with 10,000 to 10,000,000 CFU of A. fumigatus intranasally in a volume of 30 
L of 1X PBS (220). At all-time points, mice were monitored at least once daily for weight loss 
and food/water availability. Mice were euthanized when they achieved 30% or greater weight 
loss and/or became moribund (Fig 2A). 
 
Differentiating Bone Marrow Derived Macrophages 
35 
 To effectively understand, characterize and simulate this viral-fungal co-infection in cell 
culture, bone marrow derived macrophages were utilized. L-929 cell conditioned media – which 
contains the growth factor M-CSF (macrophage-colony stimulating factor) – was made by 
incubating L929 cells in DMEM (Dulbecco’s Modified Eagle Medium), 10% FBS (Fetal Bovine 
Serum) and Penicillin/Streptomycin for 10 days, and then 0.45 µm filtering the medium. Bone 
marrow was collected from the femur and tibia of WT, Nlrp3-/- and Aim2-/- mice and 
differentiated for 5 days in tissue culture dishes (150mm x 25mm) in the presence of bone 
marrow differentiation media (BMDM –recipe in Table 4) media containing L-929 cell 
conditioned medium. On day 5, now differentiated macrophages from bone marrow 
hematopoietic stems cells were removed by scraping, counted using a hemocytometer, and 
seeded into 12-well plates at a concentration of 1 x 106 cells/well within 1 mL of BMDM 
medium. These macrophages were incubated overnight to allow cells to adhere to the plastic 
wells. The next day, the macrophages were used for in vitro cell infection experiments (Fig 3A).  
 
In vitro Infection Schemes 
 Macrophages in 12-well plates were washed twice with 1 mL of 1X PBS per well and 
200 L of Roswell Park Memorial Institute-1640 (RPMI-1640) medium (Corning, catalog #10-
040e) added to each well. To add the correct volume of pathogen stock to a designated number 
of cells (Equation 2), multiplicity of infection (MOI –Equation 1) was calculated. Macrophages 
were either mock infected, single infected with either pathogen, or co-infected with both 
pathogens 3 hours apart. Mock infected macrophages were treated the same as macrophages 
single or co-infected, but without a pathogen. Single infected macrophages were treated with 10 
MOI of PR8 at 0 hour or 1 MOI of A. fumigatus at 3 hours into infection followed by incubation. 
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Co-infected macrophages were treated with 10 MOI of PR8 at 0 hour and 1 MOI of A. fumigatus 
at 3 hours into infection followed by an hour incubation. During periods of incubation, the plates 
were stored at 37C/5% CO2 and the plates were intermittently shaken every 15 to 30 minutes to 
disperse the infectious media over the cells and to prevent the cells from drying. At 4 hours into 
infection, 200 L RPMI with 20% FBS was pipetted into all wells (Fig 3B) and plates returned 
to the incubator until their designated sample collection time-point. Samples were collected at 6-, 
12-, 18- or 24-hour time points by removing the supernatant for ELISA assays and lysing the 
cells with 1X RIPA buffer and 4X SDS loading dye (recipes in Table 5 and Table 6, 
respectively). The supernatant samples were kept at -20C and cell lysates were kept at -80C 
until their analysis.  
 Enzyme-linked Immunosorbent Assay (ELISA). Cell culture supernatants for the 
cytokines IL-1β, TNF- and IL-6 were examined via ELISA. Mouse Ready-SET-Go ELISA kits 
(eBioscience; catalog #s 88-7013, 88-7324, 88-7064, respectively) were used according to the 
manufacturer’s instructions except that all antibodies and streptavidin-HRP were diluted to 1:500 
instead of 1:250. The standard curve was prepared by two-fold dilutions ranging from 1000 
pg/mL to 31.25 pg/mL (Fig 4). Upon completion of the assay, plates were immediately read at 
450 nm using a BioTek ELx808 microplate reader. 
 SDS-PAGE and Immunoblotting. Intracellular protein expression and activation in cell 
lysate samples was determined via Sodium Dodecyl Sulfate - Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) and Immunoblotting. On day 1, the cell lysate samples with 4X 
SDS loading dye added were thawed and boiled at 95C for approximately 20 minutes. Samples 
were loaded into 12% polyacrylamide gels and electrophoresed at 100V for two hours in 1X 
Tris/Glycine/SDS (running) buffer (recipes for buffers in Table 7, 8 and 9). After gel 
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electrophoresis, the gels were electrophoretically transferred onto polyvinylidene difluoride 
(PVDF) membranes (GE Health Life Sciences, catalog #10600023) at 40V for 50 minutes (Table 
10). After the transfer run was complete, PVDF membranes were blocked in blocking buffer (5% 
milk in 1X TBST) on a shaker at room temperature for 1-hour. Blocking buffer was discarded 
and replaced with protein-specific primary antibodies diluted in 5% milk in 1X TBST (recipe 
from Table 8 and 11). Membranes in antibody solution were incubated on a shaker at 4C 
overnight. Day 2: The diluted primary antibody was removed and saved, and the membranes 
were washed 3 times with approximately 10 mL of 1X TBST for 10 to 20 minutes shaking per 
wash at room temperature. After the last wash was discarded, the membranes were incubated in 
primary antibody-specific secondary HRP conjugated antibodies diluted in 5% milk + TBST 
(Table 12). Membranes were incubated at room temperature for around 45 minutes with gentle 
shaking. After the secondary antibody was removed and saved, the membranes were washed 4 
times with 10 mL of 1X TBST at room temperature with vigorous shaking for approximately 10 
to 20 minutes for each wash. After the last wash was discarded, fresh 1X TBST was added to 
each membrane and membranes were transferred to a clean container where they were treated for 
one minute with 1 mL of substrate per membrane (Super Signal West Femto Maximum 
Sensitivity Substrate; ThermoFisher Scientific, catalog #34096). Separated protein bands were 
visualized using the Azure Biosystems C300 digital imaging system. 
 Mitochondrial Damage via Flow Cytometry.  To determine possible causation of the 
enhanced activation of caspase-1-p20, macrophages were stained with fluorescent dyes designed 
to detect mitochondrial damage through reactive oxygen species production originating from the 
mitochondria (MitoSOX; ThermoFisher, catalog #M36008). Macrophages were mock, single or 
co-infected as described above in the ‘In vitro Infection Schemes’ section. At 18- or 24-hours but 
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30 minutes before collecting the samples, 25 L of MitoSOX diluted in RPMI was pipetted into 
each well (at a final concentration of 2.5 nM MitoSOX). Each flow cytometry experiment had at 
least one control well left unstained. The samples in the plates were left in the biosafety cabinet 
to incubate in the dark at room temperature for approximately 30 minutes. After the 30-minute 
incubation, the media of each sample was replaced with 1 mL of warmed (37C) PBS. 
Macrophages were scraped off the plates with a 200 L pipette tip (turned upside-down). The 
macrophages, now lifted into the PBS, were transferred into a 1.5 mL centrifuge tube and 
analyzed on the Attune NxT Flow Cytometer using the BL3 channel for MitoSOX. Per sample, 
10,000 events were analyzed for fluorescence intensity and percent positivity for the dye. 
 RNA Isolation. Gene expression of hypothesized genes that could play key roles in the 
production of inflammatory cytokines were examined against β-Actin as the control: Aim2 and 
Dapk1. Macrophages were prepared and infected as previously described. At 6-, 12- and 24-
hours after infection, the supernatant was removed (kept for ELISA) and 500 L of TRIZOL 
(Invitrogen, catalog #AM97381) was added to each well and incubated for 5 minutes at room 
temperature to extract the total mRNA from the samples. TRIZOL lysed cell samples (0.5 mL) 
were transferred to labeled 1.5 mL centrifuge tubes and 100 L of chloroform was added to each 
sample. Tubes were shaken vigorously by hand for about 15 seconds and incubated at room 
temperature for 3 minutes. Tubes were centrifuged at 12,000 x g for 15 minutes at 4C. The clear 
aqueous phase (top layer) was carefully pipetted off and transferred to new labeled tubes. Next, 
the addition of isopropanol (250 L) was used to precipitate out the nucleic acids. The samples 
were shaken by hand and incubated at room temperature for 10 minutes before centrifugation at 
12,000 x g for 10 minutes at 4C. All of the supernatant was removed but approximately 5 L. 
This was done to avoid discarding the RNA pellet. The sample RNA pellets were washed with 
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75% ethanol (500 L) to remove excess salt content from the pellet. Tubes were vortexed briefly 
for 5 seconds and centrifuged at 7,500 x g for 5 minutes at 4C. The ethanol was removed and 
dried cap-open within a vacuum centrifuge. Once the pellet was almost completely dried, 20 L 
of nuclease-free water was pipetted into each tube to reconstitute the RNA pellet back into 
solution. The concentrations of the RNA samples were measured using an Implen 
Nanophotometer. All samples were normalized to 200 ng/L by adding additional nuclease-free 
water to each sample (Equation 3).  
 cDNA Synthesis and qRT-PCR. Due to the instability of RNA, this nucleic acid must 
be reverse transcribed into complementary DNA (cDNA) to be used. The High Capacity cDNA 
Reverse Transcriptase Kit (ThermoFisher Scientific, catalog #436881) was used to reverse-
transcribe mRNA into cDNA according to the manufacturer’s instructions using 1 µg total RNA 
(Table 1). cDNA samples were diluted 1:5 (80 L of nuclease-free water to the 20 L of 
amplicon solution). 5 L of the diluted cDNA samples and 2-fold standard curve samples were 
analyzed via quantitative real-time PCR (qRT-PCR) utilizing the DyNAmo HS SYBR Green 
qPCR Kits (ThermoFisher Scientific, catalog #F.410L) according to the manufacturer’s 
directions (see Table 13 for cDNA Master Mix recipe). Primers (forward and reverse) for β-
Actin, Aim2, and Dapk1 were used to test gene expression (A15612T) (see Table 14). The 
instrument used for data acquisition was a STRATAGENE-Mx3005P PCR machine. 
 
Statistical Analysis 
 For in vitro experiments with cytokine production or ROS production a one-way 
ANOVA with Tukey’s post hoc analysis was performed using GraphPad Prism 7 software 
(GraphPad Prism 7 Software, San Diego, CA, USA). For in vitro gene expression experiments 
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during certain collection time-points, a two-way ANOVA with Tukey’s post hoc analysis was 
performed using GraphPad Prism 7 software. For weight loss during in vivo experiments, a two-
way ANOVA with Tukey’s post hoc analysis was performed using GraphPad Prism 7 software. 
For survival during in vivo experiments, survival analysis was performed using the Kaplan-Meier 
Survival Plot with LogRank Test using GraphPad Prism 7 software. Any visual representations 
within figures representing immune signaling or cellular mechanisms were completed with the 
latest version of the academic membership of BioRender.com. 
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RESULTS 
 
 Although there are numerous case reports of humans contracting IAV-A. fumigatus co-
infections, there is no animal model to study the causes and contributing factors involved. For an 
animal model to be relevant, it should demonstrate similar morbidity and mortality rates 
observed in humans. As with any disease, effectively providing an in vivo model holds promise 
for understanding the causes of the disease as well as developing future treatments or vaccines. 
 
Increased Morbidity and Mortality 
 I initially infected mice intranasally with a low dose of IAV (300 PFU), which causes no 
death and only minor weight loss, and then intranasally co-infected the same mice on different 
days after the IAV infection with 107 CFU of A. fumigatus (Fig 2A). Control groups present in 
this experiment that were singly infected with IAV on day 0 (but mock co-infected on day 3) and 
singly infected with A. fumigatus on day 3 (but mock infected on day 0), showed little or no 
weight loss and almost no mortality (Fig 2B-C). However, mice coinfected on day 3 after IAV 
infection almost all died by day 10. Interestingly, mice coinfected on day 5 or day 7 after IAV 
had much less mortality (Fig 2B-C). After solidifying the ideal co-infection day as day 3, a 
separate experiment was done to determine the lethal dose of A. fumigatus needed to really cause 
severe illness during co-infection. Mice were infected with 300 PFU of PR8 intranasally on day 
0. Then, mice were infected or co-infected on day 3 with a fungal dose ranging from 104 to 107 
of A. fumigatus CFUs. All mice were monitored for weight loss and survival until day 14 after 
the initial flu infection. I observed that 104 CFU of A. fumigatus was just as efficient as 107 CFU 
at causing similar mortality during co-infection (Fig 2D-E). It should be noted that mice infected 
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with A. fumigatus alone, without prior IAV infection, scarcely lost any weight even at an 
infectious dose of 107 CFU (Fig 2D-E). A. fumigatus alone actually had significant increases in 
weight loss on various days compared to IAV (Fig 2D). This confirms previous reports that even 
a high dose of 107 A. fumigatus spores alone does not pose a threat to immunocompetent mice 
and humans [285]. Instead, the initial infection of mice with IAV must affect the immune 
response to fungal pathogens and render the mice more susceptible to the co-infection. 
 
Surge in pro-inflammatory cytokine production and caspase-1 activation during co-
infection 
 In addition to developing the mouse model for studying the factors involved in co-
infection in vivo, I also examined the immune signaling pathways involved during co-infection in 
mouse bone marrow derived macrophages (Fig 3A-C). I examined the cytokines produced by 
macrophages either mock, single or co-infected for 24 hours and found a complex ‘cytokine 
storm’ exists. Specifically, there was a dramatic increase in the level of IL-1β, IL-6 and TNF- 
during co-infection of IAV and A. fumigatus compared to mock or single infected samples (Fig 
5A-5C). In addition, IL-1β must be cleaved by caspase-1 to become active, I performed western 
blots of macrophage cell lysates either mock, single, or coinfected and found that caspase-1 
activation is dramatically elevated during co-infection. (Fig 5D). 
 Inflammasome priming stages and the overproduction of IL-1β. IL-1β is produced as 
an inactive precursor which must be cleaved to become fully active. The observed enhanced IL-
1β production during co-infection could, therefore, result due to increased expression of pro-IL-
1β or enhanced activation of IL-1β by caspase-1 within the inflammasome (Fig 6A). Previously, 
bacterial co-infections with IAV and S. pneumoniae showed similar heightened cytokine 
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production compared to preliminary observations of IAV and A. fumigatus co-infections [281-
282]. During IAV-bacterial co-infection, increased IL-1β production was associated with 
enhanced production of pro-IL-1β (283-284). Interestingly, this is exactly the opposite seen with 
co-infections with IAV and A. fumigatus. Pro-IL-1β expression was not different between IAV 
infected and IAV-fungal coinfected macrophages (Fig 6B).  
 Also, there was no increase in the activation of the transcription factor NF-B that 
controls pro-IL-1β gene expression (Fig 6B), as was seen with IAV-bacterial co-infection [283-
284]. NF-B also controls the gene expression of the inflammasome activator NLRP3 [287]. In 
agreement, there was no difference in NLRP3 in IAV or coinfected cells (Fig 7A). Thus, I 
concluded that increased expression of pro-IL-1β and NLRP3 is not responsible for enhanced 
caspase-1 activation and overproduction of IL-1β. 
 
Exploring viable agonists contributing to enhanced NLRP3 or AIM2 mediated caspase-1 
activation  
 As the first, or priming step, of NLRP3 inflammasome activation was not affected by co-
infection, I examined other possibilities. The second step in activation of the inflammasomes is 
usually provided by PRRs sensing a diverse group of agonists that can trigger the specific 
activation of the inflammasome in question. For example, NLRP3 can recognize ROS produced 
by cell damage from both IAV and A. fumigatus, and AIM2 detects DNA in the cytoplasm [278]. 
I hypothesized that if there were two pathogens, then there could be twice as much ROS or other 
cell damage. Alternatively, the co-infection could affect AIM2 sensing of fungal DNA. Either of 
these could result in increased inflammasome activation and more cytokine production.  
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 Negating ROS as a source of direct inflammasome activation through cytoplasmic 
sensing. To determine if the production of ROS facilitates the activation of NLRP3, upstream of 
caspase-1 activation during co-infection, macrophages were infected as before, and 
mitochondrial ROS was examined 18 hours into infection via flow cytometry. Based on median 
fluorescence intensity (MFI), or the median level of fluorescence detected within macrophages 
that have experienced mitochondrial damage, co-infected samples do not provide evidence that 
ROS is a primary factor in the observed over activation of caspase-1. In comparison to untreated 
samples, IAV singly infected samples produced the highest amount of ROS along with the 
observed highest percentage of ROS afflicted macrophages (Fig 7B-G). The amount of ROS 
production and percentage of ROS afflicted macrophages for the A. fumigatus singly infected 
and co-infection samples were not significant different from mock infected controls (Fig 7B-G). 
Interestingly, there are many reports of A. fumigatus inducing ROS production in host cells [286-
287]. Other reports show that melanin, within the A. fumigatus cell wall, can actually function as 
a physiological redox buffer through binding metal ions and free electrons. Either way, an 
overproduction of ROS does not occur in the co-infection samples in our experiments and 
suggests that other mechanisms for enhanced caspase-1 activation must be at play (Fig 8).  
 
Intracellular pathogen-mediated antagonistic signals contribute to the ‘perfect storm’ 
  Upon further research of the possible mechanisms for NLRP3 mediated inflammasome 
activation, several reports of a specific kinase, DAPK1, surfaced [262, 279-280]. DAPK1 
actually drives the FBXL-2-dependent proteasomal degradation of NLRP3 during A. fumigatus 
infections (see Fig 9C). This was a promising primary lead into understanding exactly how the 
two pathogens are interacting with each other and the macrophages. 
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 IAV-mediated suppression of DAPK1 gene expression promotes NLRP3 activation. 
To examine the role of DAPK1, qRT-PCR for gene expression of DAPK1 was performed on 
IAV, A. fumigatus and co-infected samples. In agreement with previous reports, A. fumigatus 
only infected macrophages showed an 8-fold increase in DAPK1 expression compared to the 
base-line in uninfected macrophages (Fig 9B). IAV, on the other hand, suppressed the expression 
of DAPK1 by four-fold compared to the uninfected macrophages (Fig 9B). Surprisingly, 
coinfected macrophages at 6h after infection also has suppressed DAPK1 expression, but this did 
increase by 24h (Fig 9B). This suggests that IAV suppresses DAPK1 expression early during co-
infection, which may prevent the proteasomal degradation of NLRP3 (Fig 9A) and allow for a 
more potent NLRP3 mediated inflammasome response during co-infection, even if NLRP3 is not 
more highly expressed by NF-κB (Fig 7A).  
 Co-infecting pathogens synergistically induce AIM2 expression. The infection of 
macrophages with A. fumigatus can also activate the AIM2 inflammasome [278]. I examined 
AIM2 gene expression using qRT-PCR and found that IAV infection alone results in highly 
induced AIM2 gene expression (Fig 10A). However, fungal infection did not greatly induce 
AIM2 expression (Fig 10A). Finally, coinfected macrophages did show high AIM2 expression, 
especially at earlier time points (Fig 10A). Thus, infection with IAV appears to induce AIM2 
gene expression, and, although AIM2 cannot detect IAV directly, because it is an RNA virus, the 
elevated AIM2 expression caused by IAV may then cause more inflammasome activation once 
the fungal co-infection occurs through the proposed pathway in Figure 10B.  
 Preliminary in vitro knockout experiments reiterate that NLRP3 and AIM2 
inflammasomes are both involved. Finally, to verify the role of AIM2 and NLRP3 during co-
infection, I infected macrophages from mice that are genetically deficient in Aim2 and Nlrp3. I 
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infected these macrophages as previously and performed ELISAs. I found that the dramatic 
increase in IL-1β and other cytokines during co-infection was muted in both the Nlrp3-/- and 
Aim2-/- macrophages (Fig 11A-F). I also observed less caspase-1 activation in Nlrp3-/- and 
Aim2-/- macrophages (Fig 11G). Overall, these data provide preliminary but essential insight into 
the inner-workings of IAV and A. fumigatus co-infections at the animal and molecular level and 
will help pave the way for future research. As IAV and A. fumigatus co-infections continue to 
gain attention, these integral cell-signaling pathways (shown in Fig 12) will promote thinking 
and discourse into how these co-infections can be prevented, diagnosed and treated. 
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DISCUSSION 
 
 
 
 In the last decade, the importance of IAV predisposing patients to opportunistic 
pathogens has become a critical area of research, mainly due to the implications for increasing 
prevention and improving the prognosis of these co-infections. Interestingly, recent research 
shows that people currently infected with IAV are confirmed to have susceptibility to 
opportunistic pathogens of fungal origin, in particular C. neoformans and C. gattii [220]. 
However, before beginning this experimental investigation of IAV and A. fumigatus, only 
clinical case reports provided information about these co-infections. Extensive research has led 
to advanced understanding regarding how to prevent and treat IAV-bacterial co-infections [284]. 
However, similar knowledge is severely lacking in IAV and A. fumigatus co-infections. Not only 
are immunocompromised individuals at risk to developing this devastating condition, but so are 
healthy people without previous serious illnesses prior to becoming infected with IAV (H1N1). 
Relevant research to IAV or A. fumigatus infections alone were used as preliminary clues to 
piece together the mystery of this co-infection [271-277].  However, it was discovered that these 
pathogens attack the host differently and there is plenty of work left to do. 
 My goal for this project, through developing an in vivo and in vitro model, was to 
interrogate how the pathogens attack the host, resulting in the observed robust immune response. 
My in vivo data clearly indicates that co-infecting with a low dose of IAV (250 to 300 PFU) on 
day 0 and 104 to 107 CFUs on day 3 results in high morbidity (% weight loss) and the highest 
observed mortality (% survivorship). Therefore, my in vivo hypothesis was supported. In 
addition, my in vitro data insightfully indicates that when co-infecting WT murine macrophages 
with IAV at hour 0 and A. fumigatus at hour 3, there is enhanced inflammation. However, this is 
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not from heightened activation of NF-B and pro-IL-1β gene transcriptional priming nor was 
higher ROS as a result of mitochondrial damage directly activating the NLRP3 inflammasome. 
Instead, my in vitro WT murine macrophage data demonstrated a vigorous production of pro-
inflammatory cytokines (IL-1β, IL-6 and TNF-) and heightened caspase-1 activation through 
an upregulated transcriptional activation of AIM2 and down regulated DAPK1. It must be noted 
that DAPK1 expression facilitates the proteasomal degradation and/or recycling of NLRP3. 
Thus, less DAPK1 could mean there is no way to shut off or eliminate NLRP3 activation, 
resulting in more caspase-1 activation. In addition, the increased expression of AIM2 could 
result in increased detection of fungal DNA in coinfected macrophages and enhanced caspase-1 
activation. In all, my data indicate that PAMPs from the pathogens and the host signaling 
pathways are a balancing-act between the activation of DAPK1, NLRP3 and AIM2.  
 As previously mentioned, NLRP3 and AIM2 are inflammasomes that function as 
cytoplasmic sensors of damage or ‘stuff’ in the case of NLRP3 and dsDNA in the case of AIM2. 
I thought that through damage elicited by IAV attacking macrophages, ROS production would 
occur. There are other research and review reports mentioning that A. fumigatus also induces 
ROS production in immune cells too [279, 287-288]. These previous reports led me to predict 
that the heightened activation of caspase-1-p20 and downstream inflammatory cytokine 
production was due more mitochondrial damage and released ROS induced by both pathogens 
combined. This, in turn, led me to formally hypothesize that the damage and the recognition of 
the fungal DNA would activate the AIM2 inflammasome along with the NLRP3 inflammasome. 
Thus, both inflammasomes would be working ‘over-time’ to try to eliminate the pathogens. This 
excessive inflammasome activation would result in an over-production of downstream mediators 
of cytokine production and release. Although I did observe more AIM2 expression, I did not 
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observe more ROS. Instead, I now propose that DAPK1 may actually mediate NLRP3 function 
through the proteasomal degradation of NLRP3.  
 IFNs and damage to infected macrophages could contribute to the activation of the 
NLRP3 inflammasome over the course of infections. When IAV infects the macrophages, 
interferons can be produced (IFN-α/β and also some reports of IFN-) and signal in an autocrine 
manner through interferon receptors like IFNAR. Transcription factors STAT1/STAT2 lead to 
the downstream expression of DAPK1. DAPK1 can then inhibits the function of the NLRP3 
inflammasome via E3 ligase mediated polyubiquitination and subsequently the protein-complex 
will be chopped up and recycled in the proteasome [262]. This would prevent excessive 
inflammation during infection [280]. However, IFN production by the host cells will block 
further virus replication. Thus, the NS1 protein is used by IAV to block further IFN production. 
Consequently, DAPK1 expression is reduced or even suppressed during IAV infection. The 
opposite is observed for A. fumigatus. In A. fumigatus singly infected samples, the production of 
IFNs induces the expression of DAPK1, as previously seen in related research [262, 280]. 
Intriguingly, during co-infection, IAV appears to override A. fumigatus, resulting in less DAPK1 
during co-infection, likely due to IAV NS1 protein initially halting IFN production. Although 
DAPK1 suppression during co-infection could result in more NLRP3 activation, this avenue of 
research needs further exploration for complete validation.  
AIM2 recognizes fungal DNA and activates the corresponding inflammasome. IAV also 
induces AIM2 expression but cannot directly activate AIM2. Instead, IAV infection can result in 
necrotic cell death and dsDNA release from host cells that then activates AIM2. During co-
infection, the increased AIM2 expression could result in more inflammasome activation due to 
enhanced AIM2 recognition of fungal DNA and host cell DNA from dead cells. Overall, the 
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increased activation of NLRP3 and AIM2 simultaneously during co-infection could result in 
increased inflammasome activation which is facilitating caspase-1 activation and release of 
cleaved IL-1β. The use of genetic knockouts for Aim2 and Nlrp3 support that these 
inflammasomes together facilitate the production of mature IL-1β, because either knockout 
resulted in lower levels of pro-inflammatory cytokines during co-infection (Fig 11A – 11F). 
Therefore, during co-infection, the signals expressed between the pathogens and the host are not 
properly regulated, explaining the rapid and inappropriate immune response observed. These 
data caused me to accept part of my initial in vitro hypothesis that NLRP3 and AIM2 
inflammasomes are activated together. However, these data caused me to reject the other part of 
this hypothesis due to the production of ROS or how the inflammasomes were becoming 
activated.  
After developing the in vivo mouse model and studying the pathways for enhanced 
caspase-1 activation and release of pro-inflammatory cytokines, many questions still remain, and 
even more questions have surfaced. To begin with, what DAMPs are contributing to the 
activation stage of the NLRP3 and AIM2 inflammasomes. It does not appear to be mitochondrial 
ROS. My prediction is either a potassium efflux from within the cell’s cytoplasm or ROS from 
ER damage is/are the DAMP(s) that is/are the direct stimuli leading to NLRP3 activation. 
Experiments are currently in the works for confirming this. Another current planned experiment 
is to determine which IFN, especially if IFN-actually is produced by macrophages through 
transcriptional gene regulation via qRT-PCR of singly infected and co-infected samples. This 
would bridge further understanding DAPK1’s and IFN-’s roles during this co-infection. Also, 
how does IAV inhibit DAPK1 and what would happen to immune signaling during co-infection 
in a Dapk1 knockout mouse? In the in vivo model, I wanted to really understand why co-
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infecting mice on day 3 with A. fumigatus produces the observed high morbidity and mortality 
rates. Previous research of other IAV co-infections highlight that the infective viral titers are 
highest during this time-point during IAV infection with H1N1 [220]. The ultimate unanswered 
question is why do mice and humans die from this co-infection? Is it due to increased 
inflammation, as seen in our macrophages, or are the pathogens growing out of control? I need to 
reexamine how low of a dose of spores can be given to elicit the same morbidity and mortality 
rates (can I go lower than 104 CFU?). Also, the dissemination of the pathogens in the body and 
organ pathologies should be considered. There are previous data within several clinical case 
reports that also identify that some patients who succumbed to this co-infection were previously 
on corticosteroids [266, 268]. What formula, strength and duration of corticosteroids and how 
does this effect the immune system during these co-infections? Could administering a common 
antiviral prevent or delay the co-infection if caught early enough? Could a possible explanation 
to decreased ROS production in co-infection samples in comparison to singly infected samples 
be due to reduced macrophage fungicidal activity through possible IFN- exposure/production?  
To sum up, a ‘perfect storm’ results from IAV and A. fumigatus co-infections, leading to 
the observed high morbidity and mortality seen in clinical case reports, and this was 
recapitulated in my in vivo mouse model (Fig 13). The ‘perfect storm’ may be caused by 
increased activation of inflammasomes, specifically AIM2 and NLRP3. This affects the 
downstream protease caspase-1 and cytokines IL-1β, IL-6 and TNF- expression. DAPK1 would 
normally decrease NLRP3 inflammasome activation, but during co-infection, IAV inhibits 
DAPK1, which results in higher NLRP3 activation. IAV also induces AIM2, which further 
induces AIM2 inflammasome activation. Hopefully, in the case of these IAV and A. fumigatus 
52 
co-infections, our research will grow the awareness and need to help the people who experience 
these robust immune responses annually during seasonal IAV pandemics. 
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Table 1. MHN Buffer Recipe.  
 
Ingredients Amount 
 
1 M MgSO4 
 
 
24.65 g 
50 mM HEPES 
 
11.915 g 
150 mM NaCl 
 
0.876 g 
Double distilled H2O Fill to 100 mL 
 
 
Table 2. 1X Plaque Assay Medium Recipe.  
 
Ingredients Amount 
 
2X MEM medium 
 
 
10.00 mL 
Molecular grade H2O 10.00 mL 
 
 
Table 3. 2X Plaque Assay Medium.  
 
Ingredients Amount 
 
Molecular grade H2O 
 
 
31.00 mL 
10X MEM 
 
10.00 mL 
100X Glutamine 
 
1.00 mL 
7.5% Bovine Serum Albumin (BSA) 4.00 mL 
  
Penicillin/Streptomycin (10,000 U/mL) 1.00 mL 
 
Sodium Bicarbonate 3.00 mL  
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Table 4. Bone Marrow Differentiating Medium Recipe.  
 
Ingredients Amount 
 
DMEM 
 
 
300.00 mL 
L-929 Medium 
 
150.00 mL 
Heat Inactivated FBS 
 
50.00 mL 
Penicillin/Streptomycin (10,000 U/mL) 5.00 mL 
  
Non-Essential Amino Acids (NEAA) 5.00 mL 
 
 
Table 5. 1X RIPA Lysis Buffer Recipe. 
 
Ingredients Final Concentration 
 
NaCl 
 
150 mM 
 
EDTA, pH 8.0 5 mM 
 
Tris, pH 8.0 
 
50 mM 
 
NP-40 (IGEPAL CA-630) 
 
1.00 % 
 
Sodium Deoxycholate 
 
0.50 % 
  
SDS 0.10% 
  
Distilled Water N/A 
  
100X Halt Protease Phosphatase Inhibitor 
Cocktail (Thermo Scientific #78442) 
 
1X 
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Table 6. 4X SDS Loading Dye Recipe.  
 
Ingredients Final Concentration 
 
Tris-Cl, pH 6.8 
 
200 mM 
 
SDS 8.00% (w/v) 
 
Bromophenol Blue 
 
0.40 % (w/v) 
 
Glycerol 
 
40.00 % 
  
-Mercaptoethanol 400 mM 
 
 
Table 7. 10X Tris Buffered Saline (TBS).  
 
Ingredients Amount 
 
Tris Base 
 
Sodium Chloride 
 
 
24.50 g 
 
87.65 g 
diH2O Fill to 1,000 mL 
 
 
Table 8. 1X Tris Buffered Saline Tween 20 (TBST).  
 
Ingredients Amount 
 
10X TBS (made previously) 
 
100.00 mL 
 
diH2O Fill to 1,000 mL 
 
Tween 20 
 
0.50 mL 
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Table 9. 1X Tris/Glycine/SDS (Running) Buffer.  
 
Ingredients Amount 
 
10X Tris/Glycine/SDS (made previously) 
 
100.00 mL 
 
diH2O Fill to 1,000 mL 
 
 
Table 10. 1X Tris/Glycine (Transfer) Buffer.  
 
Ingredients Amount 
 
diH2O 
 
900.00 mL 
 
10X Tris/Glycine (made previously) 100.00 mL 
 
Methanol 
 
200.00 mL 
 
 
Table 11. Western Blot Primary Antibodies.  
 
1 Ab Catalog # Manufacturer 
 
Anti-caspase-1 (p20) (mouse) 
 
 
AG-20B-0042-C100 
 
Adipogene 
 
Anti-β-Actin (rabbit)  
 
-Tubulin (rabbit) 
 
D6A8 
 
TU-02 
Cell Signaling 
Technologies 
 
Santa Cruz 
Biotechnology 
   
Pro-IL-1β (rabbit) D3H1Z Cell Signaling 
Technologies 
 
(Total) IB- (rabbit) 9242 Cell Signaling 
Technologies 
 
(Phosphorylated) IB-, Ser32 
(rabbit) 
14D4 Cell Signaling 
Technologies 
 
NLRP3 (rabbit) 
 
D4D8T 
 
Cell Signaling 
Technologies 
 
Caspase-8 (mouse) 
 
1C12 
 
Cell Signaling 
Technologies 
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Table 12. Western Blot Secondary Antibodies.  
 
2 Ab Catalog # Manufacturer 
 
Anti-rabbit HRP  
 
 
111-035-144 
Jackson Immuno 
Research Laboratories 
 
Anti-mouse HRP HAF007 R&D Systems 
 
 
 
Table 13. cDNA PCR Master Mix Recipe.  
 
Ingredients Amount (Kit w/o Inhibitor) 
 
10X RT Buffer 
 
2.00 L 
 
25X dNTP Mix (100mM) 0.8 L 
 
10X RT Random Primers 
 
2.00 L 
 
Multiscribe Reverse Transcriptase 
 
1.00 L 
 
Nuclease-free H2O 
 
9.2 L 
 
 
Table 14. Quantitative Real Time-PCR Primer Sequences.  
 
Specific Gene Forward Primer Reverse Primer 
 
-Actin 
 
 
5’ GGC TGT ATT CCC 
CTC CAT CG 3’ 
 
5’ CCA GTT GTT AAC 
AAT CGG ATG A 3’ 
 
Aim2 
 
 
Dapk1 
5’ GAT TCA AAG TGC 
AGG TGC GG 3’ 
 
5’ CCT GGG TCT TGA 
GGC AGA TA 3’ 
5’ TCT GAG GCT TAG 
CTT GAG GAC 3’ 
 
5’ TCG CTA ATG TTT 
CTT GCT TGG 3’ 
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Equation 1. Multiplicity of Infection for Influenza A virus (IAV) and Aspergillus fumigatus. The 
desired MOI of IAV to infect macrophages was 10 per macrophage. The desired MOI of A. 
fumigatus to infect macrophages was 1 per macrophage. 
 
1 𝑜𝑟 10 𝑀𝑂𝐼 =  
# 𝑜𝑓 𝑝𝑎𝑡ℎ𝑜𝑔𝑒𝑛𝑠
# 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 
 
Equation 2. General solving for pathogens stock volume to add. The volume of pathogen stock to 
add depends upon the number of cells present per will multiplied by the desired (previously 
calculated) MOI and divided by the known concentration of the pathogen stock solution. 
 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑝𝑎𝑡ℎ𝑜𝑔𝑒𝑛 𝑠𝑡𝑜𝑐𝑘 𝑡𝑜 𝑎𝑑𝑑 =  
# 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑤𝑒𝑙𝑙 𝑥 𝑀𝑂𝐼
[ ] 𝑜𝑓 𝑝𝑎𝑡ℎ𝑜𝑔𝑒𝑛 𝑠𝑡𝑜𝑐𝑘
 
 
 
Equation 3. Normalizing RNA concentrations. RNA concentrations were measured using a 
nanodrop and normalized using the following general calculation. 
 
(𝐶1)(𝑉1) = (𝐶2)(𝑉2 − 19𝐿) 
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Figure 1. Proposed IAV and A. fumigatus immune signaling pathways. 1) Priming stage via NF-
B activation. 2) Autocrine IFN production. 3) Damaged associated molecular patterns 
(DAMPs) inflammasome sensing and activation. 4) LC3-associated phagocytosis (LAP) 
activation. ? = undetermined involvement. Visual created in BioRender.com. 
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Figure 2. In vivo infection scheme, morbidity and mortality of infected WT mice. A) Outline of 
in vivo infection scheme created via BioRender.com. B) Weight loss in WT mice that were 
singly or co-infected on various days. C) Mortality in mice that were singly or co-infected on 
various days. D) Weight loss in WT mice infected with IAV alone, A. fumigatus at 107 CFU 
alone, or IAV co-infected with various CFU dosages of A. fumigatus on day 3. E) Mortality in 
mice infected with IAV alone, A. fumigatus at 107 alone, or IAV co-infected with various CFU 
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doses of A. fumigatus on day 3. B-E) Data were combined from 2 to 3 experiments, total n is 
indicated. Two-way ANOVA using Tukey’s post hoc analysis was utilized for statistical 
comparison for weight loss and Kaplan-Meier Survival Plot with LogRank Test was utilized for 
survival data. p values: <0.05 (*), <0.01 (**), <0.001 (***).  
 
 
  
89 
 
 
Figure 3. In vitro infection scheme. A) Process for generating macrophages from murine bone 
marrow for in vitro infections. B) In vitro infection schemes. C) Sample analysis workflow. All 
visuals created in BioRender.com. 
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Figure 4. Generating an ELISA standard curve. Graphical representation via BioRender.com of 
the process of generating an ELISA standard curve via serial dilution. 
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Figure 2. Co-infection with IAV and A. fumigatus results in overproduction of pro-inflammatory 
cytokines through enhanced caspase-1 activation. A-C) ELISAs were completed on supernatant 
from in vitro samples collected with one of the previously stated infection schemes. Data present 
2-3 independent experiments using n=2 per experiment. One-way ANOVA using Tukey’s post 
hoc analysis was utilized for statistical comparison. ns: not significant, p-values: <0.05 (*), <0.01 
(**), <0.001 (***). D) Protein levels of pro-caspase-1 and active caspase-1-p20 were measured 
using western blot analysis from differentiated macrophages infected as indicated for 24-hours. 
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Figure 3. Overproduction of IL-1β is NF-B and pro-IL-1β expression independent. A) Focused 
NF-B activation pathways that could prime inflammasome activation created in 
BioRender.com. B) Protein levels of pro-IL-1β, total IB- and phosphorylated IB- were 
measured using western blot analysis from samples collected at 6-, 12-, or 24-hours after the 
indicated infections. β-Actin was used as a control.  
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Figure 4. Negating ROS as a source of direct inflammasome activation. A) NLRP3 and -Actin 
protein expression using western blot analysis. B-G) ROS median fluorescence intensity (MFI) 
and percentage of ROS afflicted cells were analyzed by flow cytometry. One-way ANOVA 
using Dunnett’s multiple comparisons test. ns: not significant, p values: <0.05 (*), <0.01 (**), 
<0.001 (***). 
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Figure 5. Negating viable agonists contributing to the culmination of caspase-1 activation 
through inflammasome complex assembly. Recall the complete proposed signaling pathways 
that could be involved in the enhanced expression of activated caspase-1 and overproduction of 
pro-inflammatory cytokines (Figure 1). Here, updated pathways via BioRender.com show that 
NF-B dependent immune signaling does not contribute to the inflammasome activation seen at 
24-hours in co-infection samples. The production of DAMPs through mtROS as a NLRP3 
inflammasome activator has also been negated here. 
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Figure 9. Expression of DAPK1 during IAV + A. fumigatus co-infections. A) Visual explaining 
DAPK1 and NLRP3 interaction. B) mRNA from macrophage samples at 6-, 12-, or 24-h.p.i. 
examined for DAPK1 gene expression by qRT-PCR. DAPK1 mRNA was normalized relative to 
-Actin. One-way ANOVA using Tukey’s post hoc analysis was used for statistical comparison. 
p values: <0.05 (*), <0.01 (**), <0.001 (***). C) Visual proposed involvement of DAPK1’s role 
during this co-infection created via BioRender.com. 
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Figure 10. Co-infecting pathogenic agents synergistically induce AIM2 inflammasome 
activation. mRNA from differentiated macrophage samples collected at 6-, 12-, or 24-h.p.i. with 
the indicated pathogens examined for AIM2 gene expression by qRT-PCR. AIM2 mRNA was 
normalized relative to -Actin. One-way ANOVA using Tukey’s post hoc analysis used for 
statistical comparison. p values: <0.05 (*), <0.01 (**), <0.001 (***).  B) Visual of proposed 
involvement of AIM2 during this co-infection created via BioRender.com. 
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Figure 11. Preliminary in vitro experiments reiterate that NLRP3 and AIM2 inflammasomes 
independently reach similar objectives. A-F) Differentiated Nlrp3-/- and Aim2-/- knockout 
macrophage supernatants were collected from one of the previously stated infection schemes and 
analyzed via ELISA for IL-1β, IL-6 and TNF- cytokines. IL-1β, IL-6 and TNF-cytokine 
concentrations were not significantly increased during co-infection compared to uninfected or 
singly infected samples. Data presented 2-3 independent experiments using n=2 per experiment. 
One-way ANOVA using Tukey’s post hoc analysis was utilized for statistical comparison. ns: 
not significant, p-values: <0.05 (*), <0.01 (**), <0.001 (***). G) Protein levels of pro-caspase-1 
and active caspase-1-p20 were measured using western blot analysis from differentiated 
macrophages of the indicated genotype infected for 24-hours. Tubulin was used as a control.  
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Figure 12. Possible molecular signaling mechanisms left to explore. Visual representation via 
BioRender,com of the possible molecular mechanisms to examine in the future based on 
previous research. 
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Figure 13. IAV and A. fumigatus co-infection and the pivotal role of activated caspase-1. 
Understanding of the molecular mechanisms of IAV and A. fumigatus co-infections were 
severely lacking prior to this thesis research. Through development of both in vivo and in vitro 
models, a foundational understanding of the inappropriate immune signaling involved. This 
inappropriate immune signaling can begin to effectively explain the resulting high percentages of 
morbidity and mortality reported with these co-infections. Hopefully this research will begin to 
increase the attention and lead to innovative treatments soon. Visual created in BioRender.com. 
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